# Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

> **NCT07195591** · PHASE3 · RECRUITING · sponsor: **GT Medical Technologies, Inc.** · enrollment: 766 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DEVICE:** GammaTile®
- **RADIATION:** External Beam Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT07195591
- **Lead sponsor:** GT Medical Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2031-12
- **Final completion:** 2031-12
- **Target enrollment:** 766 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07195591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07195591, "Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07195591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*